- Home
- STTK vs FPAY Comparison
STTK vs FPAY Comparison
Compare STTK & FPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FPAY
- Stock Information
- Founded
- STTK 2016
- FPAY 2003
- Country
- STTK United States
- FPAY United States
- Employees
- STTK N/A
- FPAY N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FPAY Diversified Commercial Services
- Sector
- STTK Health Care
- FPAY Consumer Discretionary
- Exchange
- STTK Nasdaq
- FPAY Nasdaq
- Market Cap
- STTK 56.8M
- FPAY 46.4M
- IPO Year
- STTK 2020
- FPAY N/A
- Fundamental
- Price
- STTK $1.11
- FPAY $1.66
- Analyst Decision
- STTK Hold
- FPAY Strong Buy
- Analyst Count
- STTK 3
- FPAY 2
- Target Price
- STTK $2.00
- FPAY $3.25
- AVG Volume (30 Days)
- STTK 172.1K
- FPAY 409.0K
- Earning Date
- STTK 02-27-2025
- FPAY 11-14-2024
- Dividend Yield
- STTK N/A
- FPAY N/A
- EPS Growth
- STTK N/A
- FPAY N/A
- EPS
- STTK N/A
- FPAY N/A
- Revenue
- STTK $6,435,000.00
- FPAY $134,563,007.00
- Revenue This Year
- STTK $313.04
- FPAY $25.78
- Revenue Next Year
- STTK N/A
- FPAY $6.46
- P/E Ratio
- STTK N/A
- FPAY N/A
- Revenue Growth
- STTK 382.75
- FPAY 24.46
- 52 Week Low
- STTK $0.94
- FPAY $0.97
- 52 Week High
- STTK $11.76
- FPAY $2.37
- Technical
- Relative Strength Index (RSI)
- STTK 44.36
- FPAY 47.07
- Support Level
- STTK $1.13
- FPAY $1.60
- Resistance Level
- STTK $1.22
- FPAY $2.37
- Average True Range (ATR)
- STTK 0.11
- FPAY 0.20
- MACD
- STTK -0.01
- FPAY -0.02
- Stochastic Oscillator
- STTK 15.15
- FPAY 24.47
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About FPAY FlexShopper Inc.
FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.